{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:56:13Z","timestamp":1792457773461,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.thromres.2020.07.051","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T10:51:17Z","timestamp":1596451877000},"page":"618-625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["How I treat von Willebrand disease"],"prefix":"10.1016","volume":"196","author":[{"given":"Giancarlo","family":"Castaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2020.07.051_bb0005","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.thromres.2020.07.051_bb0010","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand\u2019s disease","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.thromres.2020.07.051_bb0015","first-page":"1065","article-title":"Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation","volume":"82","author":"Castaman","year":"1999","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0020","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/bloodadvances.2019000368","article-title":"New therapies for von Willebrand disease","volume":"3","author":"Mannucci","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.thromres.2020.07.051_bb0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.07.051_bb0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1055\/s-2006-947863","article-title":"Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom national external quality assessment scheme for blood coagulation","volume":"32","author":"Kitchen","year":"2006","journal-title":"Semin Thromb Hemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0035","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1055\/s-2006-947862","article-title":"An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation","volume":"32","author":"Meijer","year":"2006","journal-title":"Semin Thromb Hemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0040","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2009-10-249102","article-title":"Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor","volume":"116","author":"Flood","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.07.051_bb0045","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/ijlh.12087","article-title":"Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease","volume":"35","author":"Verfaillie","year":"2013","journal-title":"Int J Lab Hematol."},{"key":"10.1016\/j.thromres.2020.07.051_bb0050","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/jth.14206","article-title":"The COMPASS- VWF study: An international collaborative study by expert centres to compare results from different VWF GPIb binding activity assays","volume":"16","author":"Szederjesi","year":"2018","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2018.04.015","article-title":"Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: a large international cross-laboratory study","volume":"166","author":"Favaloro","year":"2018","journal-title":"Thromb Res."},{"key":"10.1016\/j.thromres.2020.07.051_bb0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00001721-199104000-00011","article-title":"Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and II, von Willebrand\u2019s disease","volume":"2","author":"Favaloro","year":"1991","journal-title":"Blood Coagul Fibrinolysis."},{"key":"10.1016\/j.thromres.2020.07.051_bb0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/ijlh.12743","article-title":"Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF","volume":"40","author":"Jousselme","year":"2018","journal-title":"Int J Lab Hematol."},{"key":"10.1016\/j.thromres.2020.07.051_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/rth2.12064","article-title":"Current issues in diagnosis and treatment of von Willebrand disease","volume":"2","author":"Keesler","year":"2018","journal-title":"Res Pract Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0075","doi-asserted-by":"crossref","first-page":"13835","DOI":"10.1016\/S0021-9258(19)76501-6","article-title":"Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III","volume":"262","author":"Pareti","year":"1987","journal-title":"J Biol Chem."},{"key":"10.1016\/j.thromres.2020.07.051_bb0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0029-1214149","article-title":"Toward a new paradigm for the identification and functional characterization of von Willebrand disease","volume":"35","author":"Favaloro","year":"2009","journal-title":"Semin Thromb Hemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0085","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1055\/s-0037-1616142","article-title":"Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen","volume":"86","author":"Ribba","year":"2001","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0090","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2008-10-184317","article-title":"Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von willebrand factor","volume":"114","author":"Riddell","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.07.051_bb0095","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1538-7836.2012.04746.x","article-title":"Critical von Willebrand factor A1 domain residues influence type VI collagen binding","volume":"10","author":"Flood","year":"2012","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"67","author":"Laffan","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.thromres.2020.07.051_bb0105","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood-2007-08-105940","article-title":"Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach","volume":"111","author":"Tosetto","year":"2008","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.thromres.2020.07.051_bb0110","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2020.07.051_bb0115","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0038-1635279","article-title":"Application of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self-administered questionnaire with binary questions","volume":"19","author":"Wahlberg","year":"1980","journal-title":"Methods Infect Med."},{"issue":"13","key":"10.1016\/j.thromres.2020.07.051_bb0120","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/archinte.1995.00430130095010","article-title":"Usefulness of patient interview in bleeding disorders","volume":"155","author":"Sramek","year":"1995","journal-title":"Arch Intern Med."},{"issue":"12","key":"10.1016\/j.thromres.2020.07.051_bb0125","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1538-7836.2005.01663.x","article-title":"The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study","volume":"3","author":"Rodeghiero","year":"2005","journal-title":"J Thromb Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2020.07.051_bb0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2516.2007.01648.x","article-title":"Bleeding scores in inherited bleeding disorders: clinical or research tools?","volume":"14","author":"Tosetto","year":"2008","journal-title":"Haemophilia."},{"issue":"9","key":"10.1016\/j.thromres.2020.07.051_bb0135","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J Thromb Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2020.07.051_bb0140","first-page":"1158","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006; 4(4): 766\u201373. Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease","volume":"114","author":"Tosetto","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.07.051_bb0145","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/hae.12503","article-title":"Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project","volume":"20","author":"Elbatarny","year":"2014","journal-title":"Haemophilia."},{"issue":"6","key":"10.1016\/j.thromres.2020.07.051_bb0150","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1538-7836.2010.03796.x","article-title":"Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire","volume":"8","author":"Biss","year":"2010","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0155","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"Flood","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.07.051_bb0160","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood-2017-05-786699","article-title":"Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels","volume":"130","author":"Lavin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.07.051_bb0165","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2018-09-874636","article-title":"Increased galactose expression and enhanced clearance in patients with low von Willebrand factor","volume":"133","author":"Aguila","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.07.051_bb0170","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2018-10-844936","article-title":"How I treat low von Willebrand factor levels","volume":"133","author":"Lavin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.07.051_bb0175","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1160\/TH10-11-0697","article-title":"Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance","volume":"105","author":"Castaman","year":"2011","journal-title":"Thromb Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2020.07.051_bb0180","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2012.04661.x","article-title":"Different bleeding risk in type 2 A and 2 M Von Willebrand disease: a two-year prospective study in 107 patients","volume":"10","author":"Castaman","year":"2012","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ejh.13250","article-title":"Pregnancy and delivery in women with von Willebrand disease","volume":"103","author":"Castaman","year":"2019","journal-title":"Eur J Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2020.07.051_bb0190","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3324\/haematol.2009.011239","article-title":"Pregnancy and delivery in women with von Willebrand\u2019s disease and different von Willebrand factor mutations","volume":"95","author":"Castaman","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.thromres.2020.07.051_bb0195","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2014-02-557264","article-title":"The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease","volume":"123","author":"Federici","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2020.07.051_bb0200","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease","volume":"98","author":"Castaman","year":"2013","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.thromres.2020.07.051_bb0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.1992.tb04598.x","article-title":"Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP)","volume":"82","author":"Mannucci","year":"1992","journal-title":"Br J Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2020.07.051_bb0210","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood.V74.6.1997.1997","article-title":"Consistency of responses to repeated DDAVP infusions in patients with von Willebrand\u2019s disease and hemophilia A","volume":"74","author":"Rodeghiero","year":"1989","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.thromres.2020.07.051_bb0215","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study","volume":"103","author":"Federici","year":"2004","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.thromres.2020.07.051_bb0220","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD","volume":"111","author":"Castaman","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.07.051_bb0225","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1538-7836.2009.03381.x","article-title":"Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance","volume":"7: (Suppl 1)","author":"Castaman","year":"2009","journal-title":"J Thomb Haemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0230","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V99.1.180","article-title":"Reduced von Willebrand factor survival in type Vicenza von Willebrand disease","volume":"99","author":"Casonato","year":"2002","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.thromres.2020.07.051_bb0235","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2516.1996.tb00018.x","article-title":"Desmopressin and type II B von Willebrand disease","volume":"2","author":"Castaman","year":"1996","journal-title":"Hemophilia"},{"key":"10.1016\/j.thromres.2020.07.051_bb0240","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2008-04-152280","article-title":"Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients","volume":"113","author":"Federici","year":"2009","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.thromres.2020.07.051_bb0245","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.2830310310","article-title":"Hyponatremia and seizures in young children given DDAVP","volume":"31","author":"Smith","year":"1989","journal-title":"Am J Hematol."},{"issue":"2","key":"10.1016\/j.thromres.2020.07.051_bb0250","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJM198801143180215","article-title":"Myocardial infarction in a patient with hemophilia treated with DDAVP","volume":"318","author":"Bond","year":"1988","journal-title":"N Eng J Med."},{"issue":"1","key":"10.1016\/j.thromres.2020.07.051_bb0255","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ajh.2830280115","article-title":"Thrombosis following desmopressin for uremic bleeding","volume":"28","author":"Byrnes","year":"1988","journal-title":"Am J Hematol."},{"issue":"8","key":"10.1016\/j.thromres.2020.07.051_bb0260","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2004-11-4472","article-title":"Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women","volume":"105","author":"Mannucci","year":"2005","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.thromres.2020.07.051_bb0265","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","article-title":"Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial","volume":"122","author":"Mannucci","year":"2013","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.thromres.2020.07.051_bb0270","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.thromres.2020.07.051_bb0275","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jth.14313","article-title":"Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery","volume":"17","author":"Peyvandi","year":"2019","journal-title":"J Thromb Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2020.07.051_bb0280","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/14740330902719481","article-title":"The safety of plasma-derived von Willebrand\/factor VIII concentrates in the management of inherited von Willebrand disease","volume":"8","author":"Federici","year":"2009","journal-title":"Expert Opin Drug Saf."},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2020.07.051_bb0285","first-page":"s9","article-title":"Treatment of von Willebrand disease with FVIII\/VWF concentrates","volume":"9","author":"Castaman","year":"2011","journal-title":"Blood Transf."},{"issue":"10","key":"10.1016\/j.thromres.2020.07.051_bb0290","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/j.1538-7836.2005.01435.x","article-title":"Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation\/removal methods","volume":"3","author":"Goudemand","year":"2005","journal-title":"J Thromb Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2020.07.051_bb0295","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","article-title":"Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients","volume":"5","author":"Borel-Derlon","year":"2007","journal-title":"J Thromb Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2020.07.051_bb0300","first-page":"387","article-title":"Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand\u2019s disease","volume":"88","author":"Makris","year":"2002","journal-title":"Thromb Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2020.07.051_bb0305","first-page":"378","article-title":"Venous thromboembolism in von Willebrand disease","volume":"88","author":"Mannucci","year":"2002","journal-title":"Thromb Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2020.07.051_bb0310","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.mbc.0000167659.23262.18","article-title":"Long-term prophylaxis in von Willebrand disease","volume":"16","author":"Berntorp","year":"2005","journal-title":"Blood Coag Fibrinol."},{"issue":"Suppl. 5","key":"10.1016\/j.thromres.2020.07.051_bb0315","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2007.01573.x","article-title":"Highly purified VWF\/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease. The PRO.WILL study","volume":"13","author":"Federici","year":"2007","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.07.051_bb0320","article-title":"Prophylaxis in severe forms of von Willebrand\u2019s disease: results from the von Willebrand disease prophylaxis network (VWD PN)","author":"Abshire","year":"2012","journal-title":"Haemophilia."},{"issue":"2","key":"10.1016\/j.thromres.2020.07.051_bb0325","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2018-01-769018","article-title":"von Willebrand factor regulation of blood vessel formation","volume":"132","author":"Randi","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2020.07.051_bb0330","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2020.07.051_bb0335","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1600-0609.1987.tb01458.x","article-title":"Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor","volume":"39","author":"Mannucci","year":"1987","journal-title":"Eur J Hematol."},{"key":"10.1016\/j.thromres.2020.07.051_bb0340","first-page":"10","article-title":"Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand\u2019s disease and an inhibitor against von Willebrand factor","volume":"26","author":"Ciavarella","year":"1996","journal-title":"Haemostasis."},{"issue":"3","key":"10.1016\/j.thromres.2020.07.051_bb0345","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2516.2008.01668.x","article-title":"Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report","volume":"14","author":"Franchini","year":"2008","journal-title":"Haemophilia."},{"issue":"18","key":"10.1016\/j.thromres.2020.07.051_bb0350","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"Weyand","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.thromres.2020.07.051_bb0355","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.thromres.2020.07.051_bb0360","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood.V77.9.1901.1901","article-title":"Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients","volume":"77","author":"Castillo","year":"1991","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.thromres.2020.07.051_bb0365","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM199807233390407","article-title":"Hemostatic drugs","volume":"339","author":"Mannucci","year":"1998","journal-title":"N Eng J Med."},{"issue":"5","key":"10.1016\/j.thromres.2020.07.051_bb0370","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1160\/TH11-03-0180","article-title":"Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease","volume":"106","author":"De Wee","year":"2011","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.07.051_bb0375","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(97)08248-2","article-title":"Frequency of inherited bleeding disorders in women with menorrhagia","volume":"351","author":"Kadir","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.thromres.2020.07.051_bb0380","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/j.1471-0528.2004.00305.x","article-title":"The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders","volume":"111","author":"Kingman","year":"2004","journal-title":"Br J Obstet Gynaecol."},{"issue":"3","key":"10.1016\/j.thromres.2020.07.051_bb0385","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/hae.12898","article-title":"Von Willebrand factor for menorrhagia: a survey and literature review","volume":"22","author":"Ragni","year":"2016","journal-title":"Haemophilia."},{"issue":"4","key":"10.1016\/j.thromres.2020.07.051_bb0390","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.16186","article-title":"How I manage severe von Willebrand disease","volume":"87","author":"Leebeek","year":"2019","journal-title":"Br J Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2020.07.051_bb0395","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1471-0528.1998.tb10093.x","article-title":"Pregnancy in women with von Willebrand\u2019s disease or factor XI deficiency","volume":"105","author":"Kadir","year":"1998","journal-title":"Br J Obstet Gynaecol."},{"issue":"14","key":"10.1016\/j.thromres.2020.07.051_bb0400","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/bloodadvances.2018017418","article-title":"Significant gynecological bleeding in women with low von Willebrand factor","volume":"2","author":"Lavin","year":"2018","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.thromres.2020.07.051_bb0405","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2017-06-742692","article-title":"How I treat type 2B von Willebrand disease","volume":"131","author":"Kruse-Jarres","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2020.07.051_bb0410","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/hae.12635","article-title":"Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialized care: a retrospective survey","volume":"21","author":"Stoof","year":"2015","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2020.07.051_bb0415","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/hae.12568","article-title":"Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis","volume":"21","author":"James","year":"2015","journal-title":"Haemophilia."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820304321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820304321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:48:43Z","timestamp":1758736123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384820304321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":83,"alternative-id":["S0049384820304321"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.07.051","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How I treat von Willebrand disease","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.07.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}